BACKGROUND: The nature of the tumour microenvironment immune response in head and neck cancer patients has an important role in tumour development and metastasis, but it is unknown if this differs between cancer subsites or whether it is related to the peripheral immune response. METHODS: Immune cells (CD4, CD8, Foxp3) in head and neck squamous cell carcinoma tissue (HNSCC; n = 66), detected by immunohistochemistry, have been correlated with tumour subsite and immune cells in the peripheral circulation (CD4(+)CD25(High)Foxp3(+) Treg and CD4(+) T cells), identified using flow cytometry. RESULTS: Oropharyngeal tumours had a greater number of infiltrating immune cells in both tumour and stroma compared with other subsites, but no difference was observed in the circulating levels. Immune cells in the stroma were positively related to those in the tumour with consistently higher levels in stroma. A strong relationship was found between the number of CD4(+) and Foxp3(+) cells but not between the number of CD8(+) and Foxp3(+) cells in the tumour. The number of Foxp3(+) cells within the tumour was positively correlated with the percentage of circulating CD4(+)CD25(High) cells positive for Foxp3. Late stage laryngeal tumours showed a higher number of Foxp3(+) lymphocytes compared with early stage malignancies, and oropharyngeal tumours had more CD4(+) cells in node negative tumours compared with node positive ones. CONCLUSION: The level of immune cell infiltration in head and neck squamous cell carcinoma appears to be subsite dependent residing primarily in the stroma and is likely to be dependent on the peripheral immune response.
BACKGROUND: The nature of the tumour microenvironment immune response in head and neck cancerpatients has an important role in tumour development and metastasis, but it is unknown if this differs between cancer subsites or whether it is related to the peripheral immune response. METHODS: Immune cells (CD4, CD8, Foxp3) in head and neck squamous cell carcinoma tissue (HNSCC; n = 66), detected by immunohistochemistry, have been correlated with tumour subsite and immune cells in the peripheral circulation (CD4(+)CD25(High)Foxp3(+) Treg and CD4(+) T cells), identified using flow cytometry. RESULTS:Oropharyngeal tumours had a greater number of infiltrating immune cells in both tumour and stroma compared with other subsites, but no difference was observed in the circulating levels. Immune cells in the stroma were positively related to those in the tumour with consistently higher levels in stroma. A strong relationship was found between the number of CD4(+) and Foxp3(+) cells but not between the number of CD8(+) and Foxp3(+) cells in the tumour. The number of Foxp3(+) cells within the tumour was positively correlated with the percentage of circulating CD4(+)CD25(High) cells positive for Foxp3. Late stage laryngeal tumours showed a higher number of Foxp3(+) lymphocytes compared with early stage malignancies, and oropharyngeal tumours had more CD4(+) cells in node negative tumours compared with node positive ones. CONCLUSION: The level of immune cell infiltration in head and neck squamous cell carcinoma appears to be subsite dependent residing primarily in the stroma and is likely to be dependent on the peripheral immune response.
Authors: Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox Journal: Adv Anat Pathol Date: 2017-11 Impact factor: 3.875
Authors: Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox Journal: JCI Insight Date: 2017-07-20
Authors: Rodney Macedo; Juliette Rochefort; Maude Guillot-Delost; Kae Tanaka; Aline Le Moignic; Clara Noizat; Claude Baillou; Véronique Mateo; Antoine F Carpentier; Eric Tartour; Chloé Bertolus; Bertrand Bellier; Géraldine Lescaille; François M Lemoine Journal: Oncoimmunology Date: 2016-07-06 Impact factor: 8.110
Authors: E Lukesova; J Boucek; E Rotnaglova; M Salakova; E Koslabova; M Grega; T Eckschlager; B Rihova; B Prochazka; J Klozar; R Tachezy Journal: Biomed Res Int Date: 2014-04-23 Impact factor: 3.411
Authors: Giuseppe Troiano; Vito Carlo Alberto Caponio; Linda Boldrup; Xiaolian Gu; Lorenzo Lo Muzio; Nicola Sgaramella; Lixiao Wang; Karin Nylander Journal: Oncotarget Date: 2017-08-21
Authors: Alexander W Eckert; Claudia Wickenhauser; Paul C Salins; Matthias Kappler; Juergen Bukur; Barbara Seliger Journal: J Transl Med Date: 2016-04-05 Impact factor: 5.531